203 related articles for article (PubMed ID: 26674131)
1. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.
Zhao RC; Zhou J; Chen KF; Gong J; Liu J; He JY; Guan P; Li B; Qin Y
Neoplasma; 2016; 63(2):288-98. PubMed ID: 26674131
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of OCT4 is associated with low differentiation and tumor recurrence in human hepatocellular carcinoma.
Dong Z; Zeng Q; Luo H; Zou J; Cao C; Liang J; Wu D; Liu L
Pathol Res Pract; 2012 Sep; 208(9):527-33. PubMed ID: 22824146
[TBL] [Abstract][Full Text] [Related]
3. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
4. [OCT4 expression in hepatocellular carcinoma and its clinical significance].
Huang PZ; Lu CL; Li BK; Hong J; Huang L; Wang L; Zhang Y; Yuan YF
Chin J Cancer; 2010 Jan; 29(1):111-16. PubMed ID: 20038322
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
6. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma.
Cheng SW; Tsai HW; Lin YJ; Cheng PN; Chang YC; Yen CJ; Huang HP; Chuang YP; Chang TT; Lee CT; Chao A; Chou CY; Chan SH; Chow NH; Ho CL
PLoS One; 2013; 8(11):e80053. PubMed ID: 24244607
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of stemness factors Oct4 and Nanog predict liver resection.
Yin X; Li YW; Zhang BH; Ren ZG; Qiu SJ; Yi Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2877-87. PubMed ID: 22461131
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
[TBL] [Abstract][Full Text] [Related]
9. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of liver cancer stem cells by RNA-sequencing.
Ho DW; Yang ZF; Yi K; Lam CT; Ng MN; Yu WC; Lau J; Wan T; Wang X; Yan Z; Liu H; Zhang Y; Fan ST
PLoS One; 2012; 7(5):e37159. PubMed ID: 22606345
[TBL] [Abstract][Full Text] [Related]
11. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
12. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis.
Ha SY; Kim JH; Yang JW; Kim J; Kim B; Park CK
Cancer Res Treat; 2016 Jul; 48(3):1065-73. PubMed ID: 26511806
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
[TBL] [Abstract][Full Text] [Related]
14. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
15. The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus.
Shi J; He YY; Sun JX; Guo WX; Li N; Xue J; Cheng SQ
Ann Hepatol; 2015; 14(2):198-206. PubMed ID: 25671829
[TBL] [Abstract][Full Text] [Related]
16. Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
Wu G; Wilson G; Zhou G; Hebbard L; George J; Qiao L
Discov Med; 2015 Oct; 20(110):219-29. PubMed ID: 26562475
[TBL] [Abstract][Full Text] [Related]
17. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.
Fu YP; Yi Y; Huang JL; Jing CY; Sun J; Ni XC; Lu ZF; Cao Y; Zhou J; Fan J; Qiu SJ
Oncologist; 2017 May; 22(5):561-569. PubMed ID: 28438885
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
[TBL] [Abstract][Full Text] [Related]
20. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy.
Ji F; Zhang Y; Zhu ZB; Guo Y; Shen SL; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
Hum Pathol; 2019 Apr; 86():193-202. PubMed ID: 30529751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
